KRAS and neoplasm: Despite all clinical advances regarding personalized therapy, there is still a highly remarkable unmet clinical need since a very well-known and highly prevalent tumor driver mutation in NSCLC patients, such as KRAS, still remains refractory to pharmacological inhibition.